Long Si-Yu, Shang Lin, Zhao Siqi, Shi Huijuan, He Yan-Ling
Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Heliyon. 2024 May 14;10(11):e31054. doi: 10.1016/j.heliyon.2024.e31054. eCollection 2024 Jun 15.
Psoriasis is a global health concern, and biological therapies have proven to be highly effective in treating psoriatic patients in many countries. We performed a bibliometric analysis of current research on biological agents for the treatments of psoriasis, investigating research patterns and public interest in this area. We conducted a thorough review of articles on biological agents for psoriasis in the Web of Science Core Collection spanning from 2000 to 2022. Our study involved examining the distribution of these articles based on publication year, affiliations, countries, authors, and journals. To visualize this data effectively, we employed bibliometric tools like CiteSpace and the R package bibliometrix. Our analysis encompassed 8,047 publications. The number of papers published sharply increased from 2009, either reaching its peak in 2022 or not yet reaching it. The United States (n = 2,292), Kristian Reich (n = 166), and (n = 368) emerged as the top countries, author, and journal, respectively, in terms of publication productivity. The burst references predominantly focused on evaluating the safety and efficacy of biological treatments. The keyword citation network identified 11 clusters, with research themes revolving around "double blind", "efficacy", "therapy", "safety", and "psoriatic arthritis" were the research focuses. Additionally, potential future research areas such as "multicenter," "drug survival," and "severity" were emphasized. This study sheds light on the evolving research landscape and public interest in biological agents for psoriasis. The results suggest rapid expansion in this field, with the United States at the forefront. Enhanced international collaboration is recommended, and forthcoming research endeavors may concentrate on predicting treatment outcomes and adverse effects. Researching new biological agents, broadening the indications for biological agent treatment, and creating personalized treatment plans may pave the way for further research.
银屑病是一个全球性的健康问题,在许多国家,生物疗法已被证明在治疗银屑病患者方面非常有效。我们对目前关于治疗银屑病的生物制剂的研究进行了文献计量分析,调查了该领域的研究模式和公众关注度。我们对科学网核心合集中2000年至2022年期间关于银屑病生物制剂的文章进行了全面回顾。我们的研究包括根据发表年份、机构、国家、作者和期刊来考察这些文章的分布情况。为了有效地可视化这些数据,我们使用了文献计量工具,如CiteSpace和R包bibliometrix。我们的分析涵盖了8047篇出版物。发表的论文数量从2009年开始急剧增加,要么在2022年达到峰值,要么尚未达到峰值。就发表量而言,美国(n = 2292)、克里斯蒂安·赖希(n = 166)和《 》(n = 368)分别成为排名第一的国家、作者和期刊。爆发性参考文献主要集中在评估生物治疗的安全性和有效性。关键词共被引网络识别出11个聚类,围绕“双盲”“疗效”“治疗”“安全性”和“银屑病关节炎”的研究主题是研究重点。此外,还强调了“多中心”“药物生存期”和“严重程度”等潜在的未来研究领域。这项研究揭示了银屑病生物制剂不断变化的研究格局和公众关注度。结果表明该领域正在迅速扩展,美国处于领先地位。建议加强国际合作,未来的研究工作可能会集中在预测治疗结果和不良反应上。研究新型生物制剂、拓宽生物制剂治疗的适应症以及制定个性化治疗方案可能为进一步的研究铺平道路。